Skip to main content

Tebentafusp Dosage

Medically reviewed by Drugs.com. Last updated on Apr 24, 2024.

Applies to the following strengths: tebn 100 mcg/0.5 mL

Usual Adult Dose for Malignant Melanoma

20 mcg IV on Day 1, 30 mcg IV on Day 8, 68 mcg IV on Day 15, and then 68 mcg IV once a week thereafter
Duration of therapy: Until unacceptable toxicity or disease progression occur

Comments:


Use: For the treatment of HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

No dosage reduction is recommended for this drug; the following dosage modifications are recommended for adverse reactions.

CYTOKINE RELEASE SYNDROME (CRS):


SKIN REACTIONS:

ELEVATED LIVER ENZYMES:

OTHER ADVERSE REACTIONS:

Grade is based on National Cancer Institute Common Terminology Criteria for Adverse Events.

Precautions

US BOXED WARNING:


CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

IV compatibility:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.